Are Australian clinicians monitoring medication adherence in hematological cancer survivors? Two cross-sectional studies

Experimental Hematology & Oncology

Alessandra Bisquera⁴  Campbell Tiley²  William Stevenson³  Rob Sanson-Fisher²  Alix Hall²  Tara Clinton-McHarg¹  Marita C. Lynagh² 

[1] School of Medicine and Public Health, Faculty of Health and Medicine, The University of Newcastle, 1127 Booth Building, Wallsend Campus 2308, NSW, Australia;School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Level 4, West, HMRI Building, Callaghan 2308, NSW, Australia;Department of Haematology Royal North Shore Hospital Pathology North, The University of Sydney, Sydney 2006, NSW, Australia;The Clinical Research Design Information Technology and Statistical Support Unit (CReDITSS), The University of Newcastle, HMRI Building, Callaghan, Sydney 2308, NSW, Australia

关键词: Oral therapy;    Hematological cancer;    Medication adherence;   

Others  :  1220364
DOI  :  10.1186/s40164-015-0011-4

 received in 2015-03-16, accepted in 2015-06-04,  发布年份 2015

【 摘 要 】

Background

Hematological cancer survivors are growing in number and increasingly rely on oral therapy. Given known poor outcomes associated with non-adherence and previous evidence that many patients do not fully adhere to their treatment regimen, this study aimed to determine the degree to which clinicians monitor adherence to oral medication in hematological cancer survivors.

Methods

Data was combined from two cross-sectional surveys of a heterogeneous sample of 431 hematological cancer survivors recruited from three outpatient hematology clinics in three different states (n = 215) and one state cancer registry (n = 216) in Australia. Participants completed a self-administered survey that included demographic characteristics and a 7-item measure of medication adherence developed by the researchers specifically for the purpose of the studies.

Results

Of the 431 participants, 37 % (n = 160) reported currently taking daily cancer-related medication. Of these, 14 % (n = 23) were found to be non-adherent with ‘missing a dose’ being the most commonly reported non-adherent behaviour. Only 41 % of survivors indicated that their hematologist or cancer clinician had ‘always’ asked about their cancer-related medication during their last six visits.

Conclusions

Non-adherence to oral therapy remains a problem in hematological cancer survivors, yet clinicians in Australia do not appear to be regularly monitoring adherence in their patients. Given an increasing dependence on oral therapy in clinical hematology and medical oncology and the importance of medication adherence to optimising health outcomes, greater effort should be invested in developing effective interventions to improve support and adherence monitoring by cancer clinicians and GPs.

【 授权许可】

   
2015 Lynagh et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Balkrishnan R. The importance of medication adherence in improving chronic-disease related outcomes. What we know and what we need to further know. Med Care. 2005; 43(6):517-20.
• [2]Hohneker J, Shah-Mehta S, Brandt PS. Perspectives on adherence and persistence with oral mediations for cancer treatment. J Oncol Pract. 2011; 7(1):65-7.
• [3]Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA et al.. Treatment interruptions and non-adherence with Imatinib and associated healthcare costs. Pharmacoeconomics. 2007; 25(6):481-96.
• [4]Noens L, van Lierde MA, De Bock R et al.. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood. 2009; 113:5401-11.
• [5]Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M et al.. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010; 28(10):2381-8.
• [6]Ibrahim AR, Eliasson L, Apperley JF et al.. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011; 117(4):3733-6.
• [7]Richardson JL, Shelton DR, Krailo M, Levine AM. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol. 1990; 8(2):356-64.
• [8]Guidance on cancer services improving outcomes in haematological cancers: the manual. National Health Service, London; 2003.
• [9]Haematological Malignancy Model of Care. Cancer and Palliative Care Network, Department of Health WA, Perth, WA; 2009.
• [10]Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med. 2005; 353:487-97.
• [11]Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009; 59:56-66.
• [12]Elwyn G, Edwards A, Britten N. ‘Doing prescribing’: how doctors can be more effective. Br Med J. 2003; 327:864-7.
• [13]Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews 2008(Issue 2):Art. No.:CD000011.
• [14]Iihara N, Tsukamoto T, Morita S, Myoshi C, Takabatake K, Kurosaki Y. Beliefs of chronically ill Japanese patients that lead to non-intentional non-adherence to medication. J Clin Pharm Ther. 2004; 29:417-24.
• [15]Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer. 2006; 42:2271-6.
• [16]Butow P, Palmer S, Pai A, Goodenough B, Luckett T, King M. Review of adherence-related issues in adolescents and young adults with cancer. J Clin Oncol. 2010; 28(32):4800-9.
• [17]McCue DA, Lohr LK, Pick AM. Improving adherence to oral cancer therapy in clinical practice. Pharmacotherapy. 2014; 34(5):481-94.
• [18]Australian Bureau of Statisics: Information paper: Outcomes of ABS reviews on remoteness consultation, Australia. In. Edited by ABS. Canberra: ABS; 2001.
• [19]Evans J, Ziebland S, Pettitt AR. Incurable, invisible and inconclusive: watchful waiting for chronic lymphocytic leukaemia and implications for doctor-patient communication. Eur J Cancer Care. 2012; 21:67-77.
• [20]O'Brien SG, Guilhot F, Larson RA et al.. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348:994-1004.
• [21]Burnier M. Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension. Blood Pressure Monitoring. 2000; 5 Supple 1:S31-S34.
• [22]Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999; 47(6):555-67.
• [23]Fink AK, Gurwitz J, Rakowski W et al.. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2004; 22:3309-15.
• [24]Boyes AW, Girgis A, D'Este C, Zucca A. Prevalence and correlates of cancer survivors' supportive care needs 6 months after diagnosis: A population-based cross-sectional study. BMC Cancer 2012, 12(150).
• [25]Smith T, Stein KD, Mehta CC, Kaw C, Kepner JL, Buskirk T et al.. The rationale, design and implementation of the American Cancer Society's studies of cancer survivors. Cancer. 2007; 109:1-12.